JD Health International Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Enlin Jin
Chief executive officer
CN¥8.4m
Total compensation
| CEO salary percentage | 15.0% |
| CEO tenure | 2.9yrs |
| CEO ownership | 0.01% |
| Management average tenure | no data |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
The Returns On Capital At JD Health International (HKG:6618) Don't Inspire Confidence
Aug 08
Why We're Not Concerned About JD Health International Inc.'s (HKG:6618) Share Price
Jul 21This Is Why JD Health International Inc.'s (HKG:6618) CEO Compensation Looks Appropriate
Jun 14Calculating The Intrinsic Value Of JD Health International Inc. (HKG:6618)
May 21JD Health International Inc.'s (HKG:6618) Stock Retreats 30% But Earnings Haven't Escaped The Attention Of Investors
Apr 17JD Health International (HKG:6618) Is Reinvesting At Lower Rates Of Return
Apr 08At HK$29.80, Is It Time To Put JD Health International Inc. (HKG:6618) On Your Watch List?
Mar 01Revenues Tell The Story For JD Health International Inc. (HKG:6618)
Jan 16JD Health International (HKG:6618) Will Want To Turn Around Its Return Trends
Dec 07What Does JD Health International Inc.'s (HKG:6618) Share Price Indicate?
Nov 20JD Health International Inc. (HKG:6618) Shares Could Be 44% Below Their Intrinsic Value Estimate
Nov 02Be Wary Of JD Health International (HKG:6618) And Its Returns On Capital
Aug 21JD Health International Inc.'s (HKG:6618) Intrinsic Value Is Potentially 32% Above Its Share Price
Aug 03JD Health International Inc.'s (HKG:6618) Price In Tune With Revenues
Jun 08Is JD Health International Inc. (HKG:6618) Trading At A 32% Discount?
Apr 19Estimating The Intrinsic Value Of JD Health International Inc. (HKG:6618)
Dec 29Is There An Opportunity With JD Health International Inc.'s (HKG:6618) 31% Undervaluation?
Sep 14A Look At The Fair Value Of JD Health International Inc. (HKG:6618)
Dec 04Calculating The Fair Value Of JD Health International Inc. (HKG:6618)
Mar 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥3b |
| Mar 31 2024 | n/a | n/a | CN¥2b |
| Dec 31 2023 | CN¥8m | CN¥1m | CN¥2b |
| Sep 30 2023 | n/a | n/a | CN¥2b |
| Jun 30 2023 | n/a | n/a | CN¥2b |
| Mar 31 2023 | n/a | n/a | CN¥1b |
| Dec 31 2022 | CN¥8m | CN¥1m | CN¥380m |
| Sep 30 2022 | n/a | n/a | -CN¥7m |
| Jun 30 2022 | n/a | n/a | -CN¥395m |
| Mar 31 2022 | n/a | n/a | -CN¥734m |
| Dec 31 2021 | CN¥3m | CN¥301k | -CN¥1b |
Compensation vs Market: Enlin's total compensation ($USD1.17M) is about average for companies of similar size in the Hong Kong market ($USD908.91K).
Compensation vs Earnings: Enlin's compensation has been consistent with company performance over the past year.
CEO
Enlin Jin (43 yo)
2.9yrs
Tenure
CN¥8,385,000
Compensation
Mr. Enlin Jin is Chief Executive Officer & Executive Director of JD Health International Inc. from September 06, 2021. Mr. Jin has extensive experience in pharmaceuticals and TMT industry. He serves as the...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 2.9yrs | CN¥8.39m | 0.011% CN¥ 7.3m | |
| Independent Non-Executive Director | 2.3yrs | CN¥818.00k | 0.00030% CN¥ 205.2k | |
| Chairman | 3.9yrs | CN¥407.82m | 0.28% CN¥ 190.5m | |
| Non-Executive Director | 4yrs | no data | no data | |
| Independent Non-Executive Director | 3.8yrs | CN¥476.00k | 0.00018% CN¥ 123.1k | |
| Independent Non-Executive Director | 3.8yrs | CN¥476.00k | 0.00018% CN¥ 123.1k | |
| Independent Non-Executive Director | 3.4yrs | CN¥463.00k | 0.00019% CN¥ 130.0k |
3.8yrs
Average Tenure
51yo
Average Age
Experienced Board: 6618's board of directors are considered experienced (3.8 years average tenure).